2021
Optimal Timing of SBRT for Treatment of Oligometastatic Disease: A Single Institution Retrospective Analysis
Gao S, Yu J, Park H, Decker R. Optimal Timing of SBRT for Treatment of Oligometastatic Disease: A Single Institution Retrospective Analysis. International Journal Of Radiation Oncology • Biology • Physics 2021, 111: e476-e477. DOI: 10.1016/j.ijrobp.2021.07.1324.Peer-Reviewed Original ResearchCurative-intent stereotactic body radiation therapyStereotactic body radiation therapyUpfront systemic therapyKarnofsky performance scoreProgression-free survivalSystemic therapyOverall survivalOligometastatic diseaseSequential therapyWorse survivalOligometastatic settingConcurrent therapyImproved survivalHigher Karnofsky performance scoreSingle-institution retrospective analysisOptimal timingCox proportional hazards modelExtracranial metastatic lesionsImproved overall survivalPrimary tumor locationMajority of patientsConcurrent systemic therapyMultivariate Cox analysisBody radiation therapyProportional hazards model
2020
Proceedings of the ASTRO-RSNA Oligometastatic Disease Research Workshop
Yu JB, Brock KK, Campbell AM, Chen A, Diaz R, Escorcia F, Gupta G, Hrinivich WT, Joseph S, Korpics M, Onderdonk BE, Pandit-Taskar N, Wood B, Woodward WA. Proceedings of the ASTRO-RSNA Oligometastatic Disease Research Workshop. International Journal Of Radiation Oncology • Biology • Physics 2020, 108: 539-545. PMID: 32434040, DOI: 10.1016/j.ijrobp.2020.05.018.Peer-Reviewed Original ResearchConceptsOligometastatic diseaseRadiation oncologyAmerican SocietyOligometastatic stateImmune therapyDefining oligometastatic disease from a radiation oncology perspective: An ESTRO-ASTRO consensus document
Lievens Y, Guckenberger M, Gomez D, Hoyer M, Iyengar P, Kindts I, Méndez Romero A, Nevens D, Palma D, Park C, Ricardi U, Scorsetti M, Yu J, Woodward W. Defining oligometastatic disease from a radiation oncology perspective: An ESTRO-ASTRO consensus document. Radiotherapy And Oncology 2020, 148: 157-166. PMID: 32388150, DOI: 10.1016/j.radonc.2020.04.003.Peer-Reviewed Original ResearchConceptsMetastasis-directed radiotherapyDefinition of oligometastatic diseaseOligometastatic diseaseMetastatic sitesAbsence of clinical dataMetachronous oligometastatic diseaseRadiation oncology perspectiveDisease-free intervalSingle-centre seriesContext of radiotherapyPatient inclusion criteriaProgression-freeMetastatic locationsCurative intentMetastatic lesionsOverall survivalPrimary tumorSystemic therapyOncological perspectiveQuality-of-lifeClinical dataRadiotherapyLocal controlConsensus documentInclusion criteria
2017
Stereotactic Body Radiation Therapy for Oligometastatic Disease: A Multi-Institutional Retrospective Survival Analysis
Bui D, Magnuson W, Lester-Coll N, Qian J, Ross R, Soulos P, Shafman T, Dosoretz A, Evans S, Yu J, Gross C, Decker R. Stereotactic Body Radiation Therapy for Oligometastatic Disease: A Multi-Institutional Retrospective Survival Analysis. International Journal Of Radiation Oncology • Biology • Physics 2017, 99: e443. DOI: 10.1016/j.ijrobp.2017.06.1664.Peer-Reviewed Original ResearchStereotactic body radiation therapyRetrospective survival analysisBody radiation therapyOligometastatic disease